A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or pemetrexed) alone in patients with previously treated advanced NSCLC.
Non-Small-Cell Lung Carcinoma
Neoplasm Recurrence, Local
Drug: Avastin (bevacizumab)
Drug: Tarceva (erlotinib HCl)
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy (Docetaxel or Pemetrexed) or Tarceva (Erlotinib) Compared With Chemotherapy (Docetaxel or Pemetrexed) Alone for Treatment of Recurrent or Refractory Non-Small Cell Lung Cancer|
- To evaluate the safety and preliminary efficacy of combining bevacizumab with chemotherapy or Tarceva relative to chemotherapy alone on patients with previously treated advanced non-small cell lung cancer.
|Study Start Date:||July 2004|
|Study Completion Date:||November 2006|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00095225
Show 48 Study Locations
|Study Director:||Vince O'Neill, M.D.||Genentech, Inc.|